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was low. Further, the result needs to be veriﬁed by other
laboratory diagnosis methods in case of Pott’s disease.
OL-039 Can Mycobacterium tuberculosis DNA be
detected in plasma/serum samples from
tuberculosis patients?
D. Chen1 *, B. Gu1, S.Y. Pan1, H. Wang1, Z.H. Yan1,
C. Zhao1, G.Y. Liu1. 1Department of Laboratory Medicine,
the First Afﬁliated Hospital of Nanjing Medical University,
China
Background: Tests based on PCR have shown promise for the
detection of M. tuberculosis in different clinical samples
except plasma/serum. The purpose of this study was to
know that whether M. tuberculosis DNA can be detected in
plasma/serum samples.
Methods: 43 serums and 94 plasma were collected
from 124 clinical diagnosed TB patients. Four different
M. tuberculosis DNA extraction methods, including phenol-
chloroform method, Qiagen kit, Omega kit and magnetic
bead method were compared to get higher sensitivity. One
quantitative ﬂuorescent PCR designed by this study was
used for the detection of M. tuberculosis DNA.
Results: The highest DNA extraction efﬁciency (52.8%)
and the best reproducibility (CV = 26.7%) were seen in
the magnetic bead method. And M. tuberculosis DNA can
really be detected in some samples, and 39 of the 124
(31.5%) TB patients showed M. tuberculosis DNA positive in
plasma/serum samples. Interestingly, 35.3% (12/34) smear
negative cases demonstrate M. tuberculosis DNA positive.
Conclusion: In conclusion, this is the ﬁrst study to
report the existence of circulating M. tuberculosis DNA in
plasma/serum from tuberculosis patients and showed that
the detection of M. tuberculosis DNA may provide valuable
information for the diagnosis of AFB negative TB patients.
OL-040 Rapid identiﬁcation and molecular
characterization of drug resistant
Mycobacterium tuberculosis isolates circulating
in China by multilocus PCR and electrospray
ionization mass spectrometry
F.F. Wang1 *, D.J. Ecker2, W.H. Zhang1, Y.-W. Tang3.
1Department of Infectious Diseases, Huashan Hospital,
Fudan University, Shanghai, China, 2Ibis Biosciences,
Inc., a subsidiary of Abbott Molecular, Inc., Carlsbad,
CA, 2Departments of Pathology and Medicine, Vanderbilt
University Medical Center, Nashville, TN, USA
Objective: The emergence of multidrug-resistant (MDR)-TB
and more recently, of extensively drug-resistant (XDR)-TB is
a real threat to achieve TB control and elimination. Quick
detection of drug resistance is an urgent clinical need for
personalized treatment to control MDR-TB or XDR-TB.
Methods: We used multilocus PCR and electrospray
ionization mass spectrometry (PCR/ESI-MS) to determine the
genotype and drug resistance proﬁles for 96 Mycobacterium
tuberculosis isolates circulating in low and high endemic
regions (Shanghai, n = 49; Chongqing, n = 47) in China.
Results: The mutation proﬁles obtained by the PCR/ESI-MS
assay indicated that Principal Genetic Group 1 (PGG1) proﬁle
(87.5%) was dominant across the isolates tested in China.
The results revealed that a cluster of 11 isolates with katG
S315T & inhA promoter C-15T, rpoB S531L, and embB M306I
in Chongqing, the high TB endemic region, which was not
observed in Shanghai, the low endemic region. In addition,
another resistance mutation proﬁle with katG S315T & inhA
promoter T-8C, rpoB D516G & P564R/A, was detected in
10 isolates in high endemic region in comparison to one
in low endemic region. Drug-resistant gene mutations were
more diversiﬁed in the low endemic region than in the high
endemic region.
Conclusion: PCR/ESI-MS can provide another rapid and
accurate laboratory diagnostic tool for antituberculosis drug
resistance determination. This new technique has potential
to facilitate rapid determination of MDR-TB in China,
allowing timely guidance for individualized treatment.
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PL-006 HBV infection modeling and numerical
simulation for anti-HBV infection personalized
combination therapy
X. Chen1, L.Q. Min1 *, Y.A. Ye2, Q. Zhang1. 1University
of Science and Technology Beijing, 2Traditional Chinese
Internal Medicine Key Laboratory of China Education
Ministry, Dongzhimen Hospital, Beijing University of
Chinese Medicine, China
Background: Some chronic HBV (CHB) patients have normal
ALTs and hepatic injuries. Chinese herbal medicine and
nucleosides combination treatments may be effective for
some of such kind patients. It needs to develop an anti-HBV
infection treatment model to interpret the mechanism for
curable CHB patients with near normal liver functions.
Methods: A 57 years old male chronic HBeAg positive patient
(nucleosides-native) received Chinese Herbal Medicine (CHM
15 23 ingredients, 450 600 g) treatment two times daily
for 24 weeks, switched to CHM + Adefovir Dipivoxil for
53 weeks, then switched to CHM + Entecavir for 21 weeks.
A new differential equation model is introduced to describe
the dynamics of anti-HBV infection treatment, in which
a term is in charge of killing virus rather than infected
hepatocytes.
Results: His HBeAg got seroconversion at week 98. The
numerical simulation of the model and his HBV DNA, ALT
are shown in following ﬁgure.
Conclusions: Analysis shows that a treated CHB patient
with infective number R0 < 1 will eventually be cured. Large
value of that term makes patient’s virus be eventually
cleared without damaging hepatocytes.
Acknowledgment: This work is supported by the 11 5 Key
Special Project of China (No. 2008ZX10005 006).
OL-041 Evaluation of serum level changes of
sCD26 & sCD30 before and after treatment
with interferon among naive chronic hepatitis B
patients
M. Alavi-Moghaddam1 *. 1Shahid Beheshti University Of
Medical Sciences, Iran
Propose: To evaluate the role of serum levels of sCD26
and sCD30 in predicting the outcome of therapy with IFNa
among naïve chronic hepatitis B patients.
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Methods: Among 33 naïve chronic hepatitis B patients, the
serum level Changes of sCD26 and sCD30 before, 1 and
3 months after the start of therapy with IFNa were evaluated
using sandwich enzyme-linked immonosorbant assay. The
success Rate of treatment with IFNa was also obtained in
these patients.
Result: sCD26 serum level changes before the start of
therapy till one month (P= 0.001) and three months
(P< 0.001) after the start of therapy were related to success
rate of therapy. sCD30 serum level changes were not related
to treatment success.
Conclusion: Using changes of serum level of sCD26 might
be useful in predicting the outcome of therapy in naïve
chronic hepatitis B patients undergoing treatment with
IFNa. More studies with longer follow up time in this topic
are recommended.
OL-042 HBV particles preferably induce Kupffer cells
to produce TGF-b1 over pro-inﬂammatory
cytokines
H. Li1 *, H.-W. Zheng1, H. Chen1, Z.-Z. Xing1, H. You1,
M. Cong1, J.-D. Jia1. 1Liver Research Center, Beijing
Friendship Hospital, Capital Medical University, China
Background: Kupffer cells and related cytokines are
believed to play a critical role in liver ﬁbrosis. However,
it is not clear what role Kupffer cells play in HBV-related
ﬁbrogenesis.
Methods: Primary rat Kupffer cells were cultured with
different titers of HBV particles puriﬁed from the sera
of chronic hepatitis B patients. The concentrations of
TGF-b1, IL-6, IL-1 and TNF-a in the culture supernatant
were measured every 24 hours for 7 days. The mRNA and
protein levels of these cytokine in Kupffer cells were also
analyzed by quantitative real-time PCR and Western blot,
respectively.
Results: Kupffer cells maintained normal morphology and
function throughout the 7-day HBV treatment. TGF-b1
secreted by Kupffer cells under stimulation with HBV at
6 Log IU mL 1 increased 5.38±4.54- and 7.75±4.27-fold
by Days 3 and 7, respectively (p < 0.01). Western blotting
showed the expression of TGF-b1 in Kupffer cells exposed
to high titer HBV increased from 1.80±0.20- to 2.42±0.46-
fold by Days 3 and 7, respectively (p < 0.01). In contrast,
Kupffer cell expression and secretion of proinﬂammatory
cytokines (IL-6, IL-1 and TNF-a) were unchanged throughout
the experiment.
Conclusion: HBV could preferably stimulate Kupffer cells
to produce proﬁbrogenic/anti-inﬂammtory cytokine TGF-b1
over proinﬂammatory cytokines IL-6, IL-1 and TNF-a. This in
vitro study may partly explain why overt liver ﬁbrosis still
presents in chronic HBV infection with minimal or even in
the absence of necroinﬂammation.
OL-043 HBV DNA change between HBeAg positive and
negative patients with chronic hepatitis B
J. Liu1 *, J. Zhang2, C.-S. Lin1, Z. Xu1, Z.-L. Gao1.
1Department of Infectious Diseases, The Third Afﬁliated
Hospital of Sun Yat-sen University, 2Cardiothoracic Surgery
Department, The Third Afﬁliated Hospital of Sun Yat-sen
University, China
Background: Spontaneous decrease of HBV DNA among
chronic hepatitis B (CHB) patients who were not treated
with antivirus drugs had been reported. The aim of this
study was to compare the HBV DNA change between HBeAg
positive and negative CHB patients.
Methods: Dynamic change of HBV DNA level was observed
for 12 weeks in 171 cases with admission HBV DNA level
above 10,000 copies/mL. All patients had never been
treated with antiviral or immunoregulatory drugs during
this period. HBV DNA detection were carried out every two
weeks. HBV DNA baselines, minimum level and changing
degree of HBV DNA were compared respectively between
the two groups. All the data were analyzed by software
SPSS 13.0, t-test was used to compare means and difference
was signiﬁcant statistically when P < 0.05.
Results: Among HBeAg positive patients (n = 83, 48.5%),
HBV DNA baseline, minimum level and changing degree
of HBV DNA were (7.44±1.32) copies/ml, (3.59±0.99)
copies/ml and (3.84±1.39) copies/ml, respectively; Among
HBeAg negative patients (n = 88, 51.5%), HBV DNA
baseline, minimum level and changing degree of HBV
DNA were (7.26±0.96) copies/ml, (3.93±1.18) copies/ml,
(3.35±1.070) copies/ml respectively. HBV DNA baselines had
no signiﬁcant difference statistically (t = 0.759, P = 0.449);
minimum level of HBeAg positive patients was lower than
that of HBeAg negative patients (t = 2.020, P = 0.045);
changing degree of HBV DNA of HBeAg positive patients
was greater than that of HBeAg negative patients (t = 2.363,
P = 0.027).
Conclusion: Among patients with chronic hepatitis B
underwent spontaneous HBV DNA decrease, HBeAg positive
patients were more likely to have a greater HBV DNA change
and lower minimum.
OL-044 ‘Dinucleotide-pattern’ G→A hypermutations in
the pre-core 5′-GGGG tetrad of HBe negative
hepatitis B virus (HBV) variant
M.K. Parvez1,2 *, M.S. Al-Dosari1, S. Niyazi2, R. Ali2.
1Dept. of Pharmacognosy, King Saud University College of
Pharmacy, Riyadh, Saudi Arabia, 2Ghulam Sarwar Clinic,
Patna, India
Objective: Liver-APOBEC enzyme mediated G→A
hypermutation has been reported in HBV genome that
prefers 5′GGGG tetrad substrate as an antiviral-innate
immune mechanism. We therefore, intended to analyze the
occurrence of G→A hypermutations in the in the 5′GGGG
tetrad of HBV pre-C coding sequences from HBeAg negative
patients.
Methods: Six HBeAg seronegative hepatitis B patients with
chronic liver disease were studied that fulﬁlled the inclusion
criteria: presence of chronic hepatitis: persistence of HBsAg
and anti-HBeAb seropositivity for at least 12 months, HBV
DNA seropositivity, liver ALT level >1.5× upper limit of
normal, and seronegativity for HCV and HDV. Viral DNA
were extracted from the patient’s sea and subjected to PCR-
ampliﬁcation, using pre-C/C speciﬁc primer sets followed by
direct automated sequencing. The nucleotide sequences of
HBe negative HBV variants were analyzed with that of wild
type HBV, using the on line DNA multi-alignment program.
Results: The pre-C nucleotide sequence analysis of the
six HBe negative viral variants showed classical G1896A
mutations in 3 samples. Of these, one viral sequence
showed an additional G1897A substitution, representing
a ‘dinucleotide-pattern’ hypermutation resulting in pre-C
stop codon (UGG→UAA) in the 5′GGGG tetrad. In another
sample, a second G1899A substitution was also identiﬁed in
the same tetrad stetch, but in the next codon (UGGGGC→
UAGGAC).
Conclusion(s): (1) The pre-C 5′GGGG stretch appears as a
hot-spot for G→A stop codon-mutations in the HBe negative
chronic hepatitis B patients, and (2) This ‘dinucleotide-
pattern’ G→A hypermutation are likely to be introduced by
the host-APOBEC enzymes.
